Lobe Competitors

OTC Stocks . USA . 
Stock . Lobe Sciences
LOBEF Stock  USD 0.01  0.01  950.00%   
Lobe Sciences competes with Genomma Lab; as well as few others. The company classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. Analyzing Lobe Sciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Lobe Sciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Lobe Sciences Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Lobe Sciences competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lobe Sciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.000.0150.45
Details
Intrinsic
Valuation
LowRealHigh
0.000.0150.45
Details
Naive
Forecast
LowNextHigh
0.00020.01324.35
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
-0.005500.01
Details

Lobe Sciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Lobe Sciences and its competitors represents the degree of relationship between the price movements of corresponding otcs. A correlation of about +1.0 implies that the price of Lobe and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Lobe Sciences does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
CVGRF
+ 0.58
GNMLF
GCAN
+ 0.48
LRSV
LRSV
+ 0.42
GXXY
LRSV
+ 0.4
CNNA
GXXY
+ 0.35
CNNA
GCAN
+ 0.2
GXXY
  
High negative correlations   
CVGRF
- 0.7
CNNA
LRSV
- 0.67
CVGRF
LRSV
- 0.66
GNMLF
GCAN
- 0.55
GNMLF
CVGRF
- 0.49
GXXY
GCAN
- 0.33
CVGRF

Risk-Adjusted Indicators

There is a big difference between Lobe OTC Stock performing well and Lobe Sciences OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Lobe Sciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Lobe Sciences Competitive Analysis

The better you understand Lobe Sciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Lobe Sciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Lobe Sciences' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
LOBEF GRCU CNNA RMRK GXXY GNMLF CVGRF LRSV GCAN
 950.00 
 0.01 
Lobe
 50.00 
 0.0001 
Green
 3.03 
 0 
Cann
 25.00 
 0.0003 
Rimrock
 16.91 
 0.01 
Galexxy
 0.00 
 1.27 
Genomma
 0.00 
 0.01 
City
 0.00 
 0 
Link
 20.00 
 0.0004 
Greater
Market Volatility
(90 Days Market Risk)
Out of control
Out of control
Out of control
Out of control
Out of control
Dangerous
Out of control
Out of control
Out of control
Market Performance
(90 Days Performance)
Strong
Solid
Weak
Modest
Very Weak
OK
Good
Insignificant
Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
About Average
Quite High
Very High
Very High
Quite High
Low
Low
About Average
Quite High
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Hold
Strong Sell
Strong Sell
Strong Sell
Current Ratio
2.23
4.85
20.16
0.01
0.17
1.67
0.24
0.49
0.32
Net Asset
1.75 M
406
N/A
396.96 K
N/A
21.54 B
5.1 M
15.6 K
392.94 K
Profit Margin
N/A
4.96
N/A
N/A
N/A
0.081
N/A
N/A
N/A
EBITDA
(4.11 M)
861.7 K
(275.98 K)
(452.96 K)
N/A
2.84 B
(3.2 M)
N/A
(310.21 K)
Current Valuation
(6.77 M)
4.85 M
48
369.24 K
N/A
1.09 B
4.99 M
74.99 K
688.64 K
Price To Book
0.76
N/A
7.0E-4
7.41
N/A
1.38
88.0
N/A
N/A
Operating Margin
N/A
0.62
-21.26
N/A
-8.06
0.2
-15.8
N/A
N/A
Retained Earnings
N/A
(1.58 M)
(4 M)
(4.47 M)
N/A
N/A
N/A
(1.59 M)
N/A
Current Asset
N/A
N/A
N/A
5 K
N/A
N/A
N/A
171 K
N/A
Beta
2.64
1.09
1.21
1.01
1.73
0.53
2.1
2.84
1.28
Number Of Employees
3
20
1
2
2
2.3 K
2
2
1
Shares Outstanding
76.97 M
N/A
4.44 K
780.76 M
N/A
1 B
321.26 M
749.95 M
668.64 M
Cash Flow From Operations
(2.73 M)
(73.09 K)
(244.54 K)
(284.62 K)
(96.96 K)
1.47 B
(117.53 K)
(96.95 K)
(235.43 K)
Annual Yield
N/A
N/A
N/A
N/A
N/A
0.0472
N/A
N/A
N/A
Total Debt
N/A
3.1 M
N/A
N/A
523.03 K
3.83 B
40 K
67.19 K
702.44 K
Return On Equity
-2.8
0.55
-2.6
-14.25
N/A
0.13
-4.21
N/A
N/A
Z Score
-6.6
-22.03
-12.6
-19.9
N/A
N/A
19.2
N/A
N/A
Return On Asset
-0.65
0.023
-0.85
-0.69
-1.94
0.0921
-0.28
-0.86
-0.39
Book Value Per Share
0.001
-2.23
0.001
N/A
-0.007
10.98
-0.003
-11.19
-0.001
Current Liabilities
N/A
539 K
384 K
434 K
N/A
N/A
N/A
213 K
N/A
Total Asset
1.75 M
406
417 K
396.96 K
N/A
21.54 B
5.1 M
15.6 K
392.94 K
Debt To Equity
N/A
0.091
0.14
1.08
N/A
0.51
1.1
N/A
N/A
Last Dividend Paid
N/A
N/A
N/A
N/A
N/A
0.38
N/A
N/A
N/A
Shares Owned By Institutions
N/A
N/A
N/A
N/A
N/A
29.1
N/A
N/A
N/A
Market Capitalization
2.01 M
2.54 M
421
312.3 K
N/A
973.77 M
1.29 M
4.27 M
534.91 K
Price To Earning
1.34
N/A
N/A
-0.08
N/A
11.09
N/A
N/A
3.9
Price To Sales
7.72
2.8
0.0306
N/A
N/A
0.0526
13.52
N/A
50.7
Net Income
(12.25 M)
(1.09 M)
(249.82 K)
(851.33 K)
(161.23 K)
1.31 B
(4.62 M)
6.12 K
(602.23 K)
Earnings Per Share
-0.31
3.15
-0.001
-0.012
-0.003
0.07
-0.013
-36.07
-0.001
Shares Owned By Insiders
2.85
N/A
9.5
N/A
N/A
29.0
34.94
N/A
68.13
Revenue
N/A
13.17 K
13.23 K
N/A
20 K
15.49 B
N/A
N/A
12.63 K
Working Capital
N/A
(539 K)
(384 K)
(429 K)
N/A
N/A
N/A
(42 K)
N/A
Cash And Equivalents
1.38 M
80 K
59.87 K
2.22 K
97.74 K
1.3 B
9.45 K
3.56 K
311.2 K
Cash Per Share
0.04
0.04
N/A
N/A
N/A
1.3
N/A
0.19
N/A
Gross Profit
841.56 K
989.6 K
16.71 K
(161.9 K)
N/A
9.56 B
N/A
N/A
(5.03 K)
Day Typical Price
0.0109
1.0E-4
0.0024
3.0E-4
0.0113
1.27
0.0135
0.001
4.0E-4
Accumulation Distribution
5067.8
N/A
0.75
N/A
N/A
N/A
N/A
N/A
N/A
Market Facilitation Index
N/A
N/A
0.0024
N/A
N/A
N/A
N/A
N/A
N/A
Daily Balance Of Power
7.307692
(9,223,372,036,855)
(0.04)
(9,223,372,036,855)
(9,223,372,036,855)
0.0
0.0
0.0
(9,223,372,036,855)
Period Momentum Indicator
0.0095
(0.0001)
(0.0001)
(0.0001)
(0)
N/A
N/A
N/A
(0.0001)
Rate Of Daily Change
10.5
0.5
0.97
0.75
0.83
1.0
1.0
1.0
0.8
Day Median Price
0.0112
1.0E-4
0.002
3.0E-4
0.0113
1.27
0.0135
0.001
4.0E-4
Price Action Indicator
0.0041
(0.00005)
0.0012
(0.00005)
(0)
N/A
N/A
N/A
(0.00005)
Relative Strength Index
37.9
15.37
50.59
79.9
7.98
84.41
100.0
27.21
8.61
Coefficient Of Variation
286.63
520.95
5264.68
1360.66
(1,360)
1055.65
1125.54
2302.8
7657.43
Mean Deviation
222.16
38.25
7.0
8.78
4.06
2.13
3.89
7.19
10.06
Jensen Alpha
121.92
10.27
(0.05)
1.89
(0.73)
0.3342
1.37
0.4294
(0.31)
Total Risk Alpha
63.33
1.76
(1.89)
(1.31)
(2.16)
(0.36)
(0.97)
(2.46)
(2.12)
Sortino Ratio
2.31
0.1878
0.0072
0.0379
N/A
N/A
N/A
N/A
0.0032
Downside Variance
2484.17
2678.57
316.23
703.13
N/A
N/A
N/A
N/A
351.59
Standard Deviation
330.96
51.31
13.6
15.46
9.29
5.59
13.97
21.43
14.64
Kurtosis
3.29
(0.42)
5.91
0.9513
6.59
10.93
35.42
14.12
(0.22)
Potential Upside
900.0
100.0
20.0
33.33
12.97
10.31
N/A
N/A
25.0
Treynor Ratio
(2.15)
(2.74)
0.0994
(0.18)
(2.46)
0.3372
(1.05)
0.2256
0.0448
Maximum Drawdown
1266.55
150.0
89.44
58.33
67.08
41.89
95.65
150.0
68.57
Variance
109533.14
2632.28
184.89
239.07
86.27
31.28
195.3
459.37
214.35
Market Risk Adjusted Performance
(2.14)
(2.73)
0.1094
(0.17)
(2.45)
0.3472
(1.04)
0.2356
0.0548
Risk Adjusted Performance
0.2767
0.1566
0.024
0.0657
(0.05)
0.0811
0.0774
0.0428
0.0195
Skewness
2.22
0.8231
0.5032
0.5993
(0.05)
0.7907
4.38
2.55
0.4076
Semi Deviation
34.66
26.93
10.36
9.96
N/A
N/A
N/A
N/A
10.92
Information Ratio
0.3485
0.1894
0.0094
0.0651
(0.09)
0.0714
0.0795
0.0373
0.0042
Value At Risk
(90.00)
(50.00)
(24.00)
(25.00)
(18.69)
N/A
N/A
(28.57)
(20.00)
Expected Short fall
(330.66)
(100.00)
(15.65)
(33.33)
N/A
N/A
N/A
N/A
(22.33)
Downside Deviation
49.84
51.75
17.78
26.52
N/A
N/A
N/A
N/A
18.75
Semi Variance
1201.25
725.25
107.26
99.29
N/A
N/A
N/A
N/A
119.35

Lobe Sciences Competition Performance Charts

Five steps to successful analysis of Lobe Sciences Competition

Lobe Sciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Lobe Sciences in relation to its competition. Lobe Sciences' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Lobe Sciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Lobe Sciences' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Lobe Sciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Lobe Sciences position

In addition to having Lobe Sciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Corporate Bonds Funds Thematic Idea Now

Corporate Bonds Funds
Corporate Bonds Funds Theme
Funds or Etfs investing in different types of corporate debt instruments. The Corporate Bonds Funds theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate Bonds Funds Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Lobe OTC Stock

Lobe Sciences financial ratios help investors to determine whether Lobe OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Lobe with respect to the benefits of owning Lobe Sciences security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY